Ongoing TECVAYLI® (teclistamab-cqyv) Injection for subcutaneous use 10 mg/mL and 90 mg/mL or TALVEY® (talquetamab-tgvs) Injection for subcutaneous use 2 mg/mL and 40 mg/mL

TECVAYLI® and TALVEY® are two distinct bispecific antibodies with differences in dosing and administration, safety, and use.

This reference guide provides helpful information for ongoing treatment with TECVAYLI® or TALVEY®. This is not intended to be a comprehensive list, and individual practices must follow their own required procedures.

This checklist is intended for institutions who provide ongoing treatment for TECVAYLI® or TALVEY®.
Providers may utilize this checklist for their practice while either referring patients to an initiating treatment center or providing ongoing treatment.

Referring Patient to Initiating Treatment Center

- ☐ Determine the appropriate initiating treatment center for your patient based on Risk Evaluation and Mitigation Strategy (REMS) certification, geographical distance, and insurance coverage
  - ☐ *Please visit TECVAYLI.com or TALVEY.com to locate a REMS-certified treatment center with the TECVAYLI® Treatment Locator Tool/TALVEY® Treatment Locator Tool.*
- ☐ Align on patient treatment care plan and coordinate patient transfer with the initiating treatment center
  - ☐ Establish effective communication methods with initiating treatment provider(s) and/or care team
  - ☐ Forward any important discharge information, treatment notes, and records to initiating treatment site
  - ☐ Outline and discuss patient return for ongoing treatment
- ☐ Encourage the patient or their caregiver to engage the initiating treatment center for bispecific education, including outlining the step-up dosing schedule and administrative logistics

Preparing for Ongoing Treatment

- ☐ Ensure that treating prescribers and pharmacists receive REMS certification
- ☐ To ensure a successful transfer of the patient, communicate with initiating treatment site on status of the treatment plan and timing of transfer, and request all necessary transfer information (treatment notes and patient records)
- ☐ Perform benefits investigation (eg, J-Code, New Technology Add-On Payments [NTAP]) and obtain new prior authorization, if required
- ☐ Establish adverse reaction (AR) protocols and train the corresponding staff on Cytokine Release Syndrome (CRS), Neurologic Toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and infections, as well as TALVEY®-specific AR management incidence and protocols (eg, Nurse, Advanced Practice Provider, Pharmacist, Dermatologist, Social Worker, Nutritionist, Emergency Department, Infectious Disease)
- ☐ Dosing ordering information:
  - ☐ **TECVAYLI®:** Order 153 mg/1.7 mL vial size for ongoing treatment dose; use Table 9 in the full Prescribing Information to determine number of vials required based on patient's actual body weight
  - ☐ **TALVEY®:** Order 40 mg/mL vial size for ongoing biweekly or weekly treatment dose; use Tables 11 and 12 in the full Prescribing Information to determine number of vials required based on patient's actual body weight
- ☐ Ensure supportive therapies are available for CRS and Neurologic Toxicity, including ICANS
  Please see the TECVAYLI® Dosing and AR Management Guide, the TALVEY® Treatment Management Guide or the TECVAYLI® and TALVEY® Adverse Reaction Management Guide for reference.
  - ☐ Consider asking your local Johnson & Johnson representative and/or Oncology Clinical Educator for more information on any AR management
- ☐ Confirm the patient has received and is carrying the Patient Wallet Card for either TECVAYLI® or TALVEY® as prescribed
- ☐ Consider connecting with your local Johnson & Johnson representative to receive any necessary resources or if there are any questions

Patient/Caregiver Education and Logistics for Ongoing Treatment

- ☐ Discuss the patient's step-up dosing experience and ensure the patient and caregiver understand the ongoing treatment plan for TECVAYLI® or TALVEY®
- ☐ Please see section 17 in the respective product's full Prescribing Information for patient counseling information. Also, please provide and advise the patient to read the respective product's Medication Guide
- ☐ Ensure the patient has scheduled their next treatment doses, while confirming support during treatment, including caregiver support, travel, and transportation to/from appointments
- ☐ Discuss any concerns with the patient and caregiver about ARs and recap the treatment plan if the patient experiences any symptoms of ARs
  - ☐ Provide the phone number of the treating physician and where to go if the patient experiences any ARs
  - ☐ Please see section 17 in the respective product's full Prescribing Information for patient counseling information
  - ☐ Please work with your local Johnson & Johnson representative and refer the patient and caregiver to any key resources that would be helpful

Ongoing TECVAYLI® (teclistamab-cqyv) Injection for subcutaneous use 10 mg/mL and 90 mg/mL or TALVEY® (talquetamab-tgvs) Injection for subcutaneous use 2 mg/mL and 40 mg/mL

Helpful Resources for Your Reference

TECVAYLI® Prescribing Information

TALVEY® Prescribing Information

REMS Fact Sheet and Cover Letter

TECVAYLI® Medication Guide

TALVEY® Medication Guide

Janssen CarePath Resource Guide

TECVAYLI® Dosing and AR Management Guide

TALVEY® Treatment Management Guide

TECVAYLI® Patient Brochure

TALVEY® Patient Brochure

TECVAYLI® Getting Started Guide

My Journey With TALVEY®

TECVAYLI® Caregiver Brochure

TALVEY® Caregiver Brochure

Scan the QR code to connect with a local Johnson & Johnson representative and learn more about these resources

Johnson&Johnson